The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
April 16th, 2019
21.1K views
Glioblastoma is the most common and aggressive primary brain malignancy in adults, with most tumors recurring after initial treatment. Tumor Treating Fields (TTFields) therapy is the newest treatment modality for glioblastoma. Here, we describe the proper application of TTFields-transducer arrays on patients and discuss theory and aspects of treatment.
Overview
This article discusses Tumor Treating Fields (TTFields) therapy, a novel treatment for glioblastoma, the most aggressive primary brain cancer in adults. The proper application of TTFields-transducer arrays is described, emphasizing the importance of technique in maximizing treatment efficacy.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Clinical Treatment
Background
- Glioblastoma is a highly malignant brain tumor with a high recurrence rate.
- TTFields therapy is FDA-approved and has shown efficacy in clinical trials.
- Proper application of transducer arrays is crucial for effective treatment.
- Techniques may also apply to other cancers under investigation.
Purpose of Study
- To demonstrate the step-by-step procedures for applying TTFields therapy.
- To address challenges related to surgical scars and scalp sensitivity.
- To enhance the understanding of TTFields application in glioblastoma treatment.
Methods Used
- Acquisition of MRI scans for treatment planning.
- Measurement of tumor and scalp dimensions for array placement.
- Application of transducer arrays while considering surgical scars.
- Assembly and operation of the TTFields device system.
Main Results
- Demonstrated effective placement of transducer arrays on a patient.
- Highlighted the importance of avoiding complications during application.
- Showed that TTFields disrupt mitosis in tumor cells.
- Provided insights into electric field strength variation in the brain.
Conclusions
- Proper application of TTFields can maximize treatment efficacy.
- Techniques developed may be applicable to other cancers.
- Further research is needed to optimize transducer array placement.
Frequently Asked Questions
What is TTFields therapy?
TTFields therapy is a treatment modality for glioblastoma that uses electric fields to disrupt cancer cell division.
How is TTFields applied?
TTFields are applied using transducer arrays placed on the scalp, designed based on MRI measurements.
What are the benefits of TTFields?
TTFields have been shown to improve outcomes in glioblastoma patients with minimal adverse effects.
Are there any side effects?
Most patients experience minimal side effects, such as scalp irritation, which can be managed.
Can TTFields be used for other cancers?
Research is ongoing to explore the application of TTFields in other cancers, including lung and pancreatic cancers.
How often should the arrays be changed?
The arrays should be changed every three to four days to maintain effectiveness and prevent skin irritation.
Executive Industry Relevance
Tumor Treating Fields (TTFields) therapy introduces a noninvasive modality for glioblastoma, addressing a critical need for improved therapeutic options in aggressive brain cancer. The protocol's focus on precise transducer array placement and electric field modeling supports reproducible delivery and maximizes biological impact. This approach enables more reliable integration of TTFields into clinical and translational research pipelines, supporting risk-adjusted advancement decisions in neuro-oncology portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of mitotic disruption in tumor cells via electric fields.
- Supports biological de-risking by clarifying TTFields' impact on cell division and immune response.
- Facilitates predictive confidence in target engagement through electric field modeling and array placement.
Screening & Assay Development
- Establishes standardized procedures for transducer array placement based on quantitative MRI measurements.
- Enables reproducible application of TTFields across patient-derived models and clinical settings.
- Provides a platform for evaluating combinatorial regimens and optimizing device-based interventions.
Translational & Preclinical Research
- Aligns with disease-relevant systems by modeling electric field distribution in patient-specific brain anatomy.
- Supports translational continuity from device engineering to clinical application in glioblastoma.
- Informs risk-adjusted decisions for expanding TTFields to other solid tumor indications under investigation.
Pipeline & Workflow Integration
TTFields therapy is positioned at the interface of late discovery, translational research, and clinical implementation for solid tumors, with workflow steps grounded in imaging, modeling, and device application.
- Discovery Biology: Quantitative electric field modeling supports hypothesis testing on mitotic disruption mechanisms.
- Screening: Standardized array placement protocols enable reproducible device-based intervention studies.
- Analytics: MRI-based measurements and field strength predictions provide actionable quantitative outputs.
- Translational Research: Patient-specific modeling bridges preclinical findings to clinical application in glioblastoma.
- Enterprise Reuse: Protocols for array placement and field modeling are adaptable to other anatomical sites and tumor types under investigation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in device-mediated mitotic disruption and immune modulation.
- Operational Value: Standardizes application procedures, reducing variability and supporting multi-site studies.
- Strategic Value: Enables informed go/no-go decisions for TTFields expansion into new indications.
- Portfolio Impact: Supports risk-adjusted prioritization of device-based therapies in oncology pipelines.
Implementation Considerations
- Requires expertise in neuroimaging, electric field modeling, and device application.
- Demands access to MRI infrastructure and treatment planning software for precise array placement.
- Necessitates cross-team standardization to ensure reproducibility across clinical sites.
- Adaptation to other tumor locations may require protocol modifications based on anatomical differences.
- Scalp sensitivity and device tolerability must be managed to maintain patient adherence and data integrity.
Biopharma FAQs
Why does null hypothesis testing matter for TTFields target validation?
Null hypothesis testing is essential for determining whether TTFields-induced mitotic disruption is statistically significant compared to controls, supporting robust target validation in glioblastoma research. This approach helps clarify the mechanistic basis of TTFields action and informs further development. Reliable statistical analysis underpins confidence in advancing TTFields within the discovery pipeline.
How does independent variable isolation fit TTFields electric field modeling?
Isolating variables such as array placement and electric field strength allows teams to attribute observed biological effects specifically to TTFields exposure. This precision is critical for optimizing device parameters and ensuring reproducibility across patient populations. Controlled modeling supports mechanistic de-risking and translational alignment.
What do quantitative MRI-based measurements enable in TTFields planning?
Quantitative MRI measurements provide the anatomical data required for precise transducer array placement and electric field modeling. These outputs enable personalized treatment planning and support consistent delivery of TTFields across patients. Accurate measurements are foundational for reproducible and effective therapy application.
Why are replication requirements important for TTFields protocol standardization?
Replication ensures that TTFields application protocols yield consistent results across different operators and clinical sites. Standardized procedures for array placement and device operation facilitate cross-functional collaboration and multi-center studies. This reproducibility is vital for regulatory acceptance and enterprise-scale deployment.
What statistical analysis capabilities are required before TTFields implementation?
Robust statistical analysis is needed to evaluate the efficacy and safety of TTFields therapy, including assessment of mitotic disruption and adverse event rates. Teams must be able to compare outcomes across patient cohorts and device configurations. These capabilities support data-driven decisions for clinical and translational advancement.
Chapters in this video
0:04
Title
1:40
Treatment Planning
3:14
Transducer Arrays Application
4:15
Tumor Treating Fields (TTFields) Device System Assembly and Delivery
5:36
Transducer Array Exchange
5:57
Results: Representative TTFields Transducer Array Placement and Application
7:34
Conclusion
